DrugPatentWatch Database Preview
ANGIOMAX Drug Profile
When do Angiomax patents expire, and when can generic versions of Angiomax launch?
Angiomax is a drug marketed by Sandoz Inc and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.
The generic ingredient in ANGIOMAX is bivalirudin. There are fourteen drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the bivalirudin profile page.
Summary for ANGIOMAX
Pharmacology for ANGIOMAX
| Drug Class | Anti-coagulant Direct Thrombin Inhibitor |
| Mechanism of Action | Thrombin Inhibitors |
Synonyms for ANGIOMAX
| (R,R)-2,6-Bis(4,5-dihydro-4-phenyl-2-oxazolyl)pyridine; (R,R)-2,6-Bis(4-phenyl-2-oxazolinyl)pyridine; (+)-2,6-Bis[(4R)-4-phenyl-2-oxazolin-2-yl]pyridine |
| 128270-60-0 |
| 270B600 |
| 70B600 |
| 8-Methoxy-naphtho[2,3-b]thiophen-4,9-quinone |
| AKOS015994644 |
| AM006888 |
| AN-7543 |
| Angiomax (TN) |
| Angiox |
| BC657176 |
| BG 8967 |
| BG-8967 |
| BG8967 |
| Bivalirudin |
| Bivalirudin [USAN:BAN:INN] |
| Bivalirudin [USAN:INN:BAN] |
| Bivalirudin Trifluoacetate |
| Bivalirudin Trifluoroacetate |
| bivalirudina |
| bivalirudine |
| bivalirudinum |
| C98H138N24O33 |
| C9H11NO.C2H6.CH4 |
| CHEBI:59173 |
| CHEMBL2103749 |
| D-Phenylalanyl-L-prolyl-L-arginyl-L-prolylglycylglycylglycylglycyl-L-asparaginylglycyl-L-alpha-aspartyl-L-phenylalanyl-L-alpha-glutamyl-L-alpha-glutamyl-L-isoleucyl-L-prolyl-L-alpha-glutamyl-L-alpha-glutamyl-L-tyrosyl-L-leuci |
| D03ZVY |
| D09FGS |
| D09HVL |
| D0F4HO |
| DB00006 |
| EBD32115 |
| GTPL6470 |
| Hirulog |
| Hirulog-1 |
| HS-2004 |
| J-005587 |
| KS-00002WUN |
| L-Leucine, D-phenylalanyl-L-prolyl-L-arginyl-L-prolylglycylglycylglycylglycyl-L-asparaginylglycyl-L-alpha-aspartyl-L-phenylalanyl-L-alpha-glutamyl-L-alpha-glutamyl-L-isoleucyl-L-prolyl-L-alpha-glutamyl-L-alpha-glutamyl-L-tyro |
| LS-172701 |
| MolPort-006-167-455 |
| Phe-Pro-Arg-Pro-(Gly)4 desulfato-Tyr63'-hirugen |
| Phe-Pro-Arg-Pro-(Gly)4-Asn-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-Leu |
| Phe-Pro-Arg-Pro-(Gly)4-desulfohirudin-(53-64) |
| SCHEMBL25739 |
| The Medicines Company brand of bivalirudin |
| TN9BEX005G |
| UNII-TN9BEX005G |
US Patents and Regulatory Information for ANGIOMAX
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sandoz Inc | ANGIOMAX | bivalirudin | INJECTABLE;INTRAVENOUS | 020873-001 | Dec 15, 2000 | AP | RX | Yes | Yes | ➤ Try a Free Trial | ➤ Try a Free Trial | Y | ➤ Try a Free Trial | ||
| Sandoz Inc | ANGIOMAX | bivalirudin | INJECTABLE;INTRAVENOUS | 020873-001 | Dec 15, 2000 | AP | RX | Yes | Yes | ➤ Try a Free Trial | ➤ Try a Free Trial | Y | ➤ Try a Free Trial | ||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Expired US Patents for ANGIOMAX
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Sandoz Inc | ANGIOMAX | bivalirudin | INJECTABLE;INTRAVENOUS | 020873-001 | Dec 15, 2000 | ➤ Try a Free Trial | ➤ Try a Free Trial |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
Paragraph IV (Patent) Challenges for ANGIOMAX
| Drugname | Dosage | Strength | RLD | Date |
|---|---|---|---|---|
| ➤ Subscribe | For Injection | 250 mg/vial | ➤ Subscribe | ➤ Try a Free Trial |
